Your shopping cart is currently empty

Erasin is a STAT3 inhibitor (IC50 = 9.7 μM) with higher selectivity for inhibiting STAT3 tyrosine phosphorylation than STAT5 and STAT1. It induces apoptosis in various cancer cell lines (e.g., MDA-MB-231, HCC-827) and is effective against Erlotinib-resistant cancer cells.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $45 | - | In Stock |
| Description | Erasin is a STAT3 inhibitor (IC50 = 9.7 μM) with higher selectivity for inhibiting STAT3 tyrosine phosphorylation than STAT5 and STAT1. It induces apoptosis in various cancer cell lines (e.g., MDA-MB-231, HCC-827) and is effective against Erlotinib-resistant cancer cells. |
| Targets&IC50 | STAT1:24 μM, STAT3:9.7 μM |
| In vitro | Method: HepG2 and K562 cells were treated with Erasin at concentrations of 0, 5, 10, 25, 50, and 100 μM for 24 hours, with a pre-incubation period of 1–2 hours. Following treatment, cells were stimulated with IL-6 (to activate STAT3) or IFN-γ (to activate STAT1), and tyrosine phosphorylation levels of STAT proteins were assessed. Result: Erasin inhibited IL-6-induced phosphorylation of STAT3 at Tyr705 in HepG2 cells in a dose-dependent manner. It also inhibited IFN-γ-induced phosphorylation of STAT1 at Tyr701 to a lesser extent. Tyrosine phosphorylation of STAT5 in K562 cells was not inhibited.[1] |
| Molecular Weight | 349.38 |
| Formula | C20H19N3O3 |
| Smiles | CC(C)(C)C1=CC(C2=O)=C(C=C1)OC=C2/C=N/NC(C3=CC=CN=C3)=O |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 30 mg/mL (85.87 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.72 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.